Dispersion test results with multiple geometries at RBCC-E campaign AROSA 2014

Presentación realizada para el MC and WG meeting celebrado en Delft (Países Bajos) del 11 al 12 de noviembre de 201

Regional Brewer Calibration Centre-Europe (RBCC-E)

Póster elaborado para el GAW 2013 Symposium celebrado los días 18-20 de marzo de 2013 en Ginebr

RBCC-E Triad: update of the triad status

Presentación realizada para el MC and WG meeting celebrado en Manchester del 26 al 27 de septiembre de 201

RBCC-E 2014 langley campaign the triad before Arosa/Davos campaing

Presentación realizada para el MC and WG meeting celebrado en Delft (Países Bajos) del 11 al 12 de noviembre de 201

Ten years of the Regional Brewer Calibration Centre Europe 2003-2013

Presentación realizada para el Eubrewnet Open Congress /14th WMO-GAW Brewer Users Group Meeting Eubrewnet & WMO GAW celebrado en Tenerife del 24 al 28 de marzo de 201

HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with fanconi anemia

Abstract We report the outcome of 12 consecutive pediatric patients with Fanconi anemia (FA) who had neither an HLA-identical sibling nor an HLA-matched unrelated donor and who were given T cell–depleted, CD34 + positively selected cells from a haploidentical related donor after a reduced-intensity, fludarabine-based conditioning regimen. Engraftment was achieved in 9 of 12 patients (75%), and the cumulative incidence of graft rejection was 17% (95% confidence interval [CI], 5% to 59%). Cumulative incidences of grades II to IV acute and chronic graft-versus-host disease were 17% (95% CI, 5% to 59%) and 35% (95% CI, 14% to 89%), respectively. The conditioning regimen was well tolerated, with no fatal regimen-related toxicity and 3 cases of grade III regimen-related toxicity. The cumulative incidence of transplant-related mortality was 17% (95% CI, 5% to 59%). The 5-year overall survival, event-free survival, and disease-free survival were 83% (95% CI, 62% to 100%), 67% (95% CI, 40% to 93%), and 83% (95% CI, 62% to 100%), respectively. These data demonstrate that a fludarabine-based conditioning regimen, followed by infusion of high doses of T cell–depleted stem cells, is able to ensure engraftment with good overall survival and disease-free survival, confirming the feasibility of haploidentical hematopoietic stem cell transplantation in FA. To the best of our knowledge, this is the largest series of hematopoietic stem cell transplantation from a haploidentical related donor in FA patients reported to date

Attenuation filter issues in brewer ozone calculations

Presentación realizada en: 13th Biennial WMO-GAW Brewer Users Group Meeting, celebrada en Beijing (China) del 12 al 16 de septiembre de 2011

The Regional Brewer Calibration Center - Europe: an overview of the X Brewer Intercomparison Campaign

Comunicación presentada en: TECO-2016 (Technical Conference on Meteorological and Environmental Instruments and Methods of Observation) celebrada en Madrid, del 27 al 30 de septiembre de 2016.The X Regional Brewer Calibration Center - Europe (RBCC-E) intercomparison campaign was held at El Arenosillo atmospheric sounding station of the Instituto Nacional de Tecnica Aeroespacial (INTA) during the period of May 25th – June 5th, 2015. This X Brewer intercomparison campaign was a joint effort of EUBREWNET and the Area of Instrumentation and Atmospheric Research of INTA, with the support of COST Action 1207. Twenty one Brewer instruments from eleven countries participated at the El Arenosillo campaign. In addition, the solar UV irradiance calibration was performed by the traveling reference standard QASUME of the World Calibration Center for UV (WCC-UV). This work shows a general overview of the ozone comparison focused on the correction of the stray light effect for the single-monochromator Brewer spectrophotometer derived by the comparison with a reference double-monochromator Brewer. At the beginning of the campaign, 16 out of the 21 participating Brewer instruments (76%) agreed to better than ± 1%, and 10 instruments (50%) agreed to better than ± 0.5%. After applying the final calibration that included the stray light correction, all working instruments agreed at the ± 0.5% level

Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term results

BACKGROUND: The aim of the present study was to evaluate the survival, efficacy and safety of a modified RADPLAT-like protocol using carboplatin instead of cisplatin. METHODS: Fifty-six patients with primary head and neck squamous cell carcinoma received 4 cycles of intra-arterial carboplatin (350 mg/m2 per cycle every 2 weeks), with concurrent three-dimensional conformal radiation therapy. RESULTS: Two major and 4 minor complications were observed. Forty-five of the 56 patients (80%) completed the protocol, while 11 (20%) patients had to discontinue the intra-arterial infusions due to the occurrence of severe haematological toxicity, but were able to complete radiotherapy. Forty-four (98%) of the 45 patients who completed the protocol and 10 (91%) of the 11 who did not, were free of disease at the end of the treatment, for a comprehensive 96% of CR overall. After a median 23.55 months (range: 2 to 58 months) of follow-up, 40 patients (71%) are alive and disease-free, 1 (2%) is alive but affected by disease and 15 (27%) have died of the disease or other causes. CONCLUSION: Intra-arterial carboplatin administration with concurrent three-dimensional conformal radiation therapy seems to be a promising alternative to RADPLAT in the treatment of advanced head and neck tumours. Haematological and non-haematological toxicities are virtually similar, but carboplatin has the advantage in that it is not nephrotoxic and can be used at very high doses without any significant increase in the extent of side effects

Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS)

Aims: The role of non-invasive telemedicine (TM) combining telemonitoring and teleintervention by videoconference (VC) in patients recently admitted due to heart failure (HF) ('vulnerable phase' HF patients) is not well established. The aim of the Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS) trial is to assess the impact on clinical outcomes of implementing a TM service based on mobile health (mHealth), which includes remote daily monitoring of biometric data and symptom reporting (telemonitoring) combined with VC structured, nurse-based follow-up (teleintervention). The results will be compared with those of the comprehensive HF usual care (UC) strategy based on face-to-face on-site visits at the vulnerable post-discharge phase. Methods and results: We designed a 24 week nationwide, multicentre, randomized, controlled, open-label, blinded endpoint adjudication trial to assess the effect on cardiovascular (CV) mortality and non-fatal HF events of a TM-based comprehensive management programme, based on mHealth, for patients with chronic HF. Approximately 508 patients with a recent hospital admission due to HF decompensation will be randomized (1:1) to either structured follow-up based on face-to-face appointments (UC group) or the delivery of health care using TM. The primary outcome will be a composite of death from CV causes or non-fatal HF events (first and recurrent) at the end of a 6 month follow-up period. Key secondary endpoints will include components of the primary event analysis, recurrent event analysis, and patient-reported outcomes. Conclusions: The HERMeS trial will assess the efficacy of a TM-based follow-up strategy for real-world 'vulnerable phase' HF patients combining telemonitoring and teleintervention